Randomized phase II trial of OK-432 in patients with malignant pleural effusion due to non-small cell lung cancer

Anticancer Research

Volumn 26, Issue 2 B, 2006, Pages 1495-1499

  Kasahara, Kazuo ^a   Shibata, Kazuhiro ^b   Shintani, Hiromoto ^c   Iwasa, Kei Ichi ^d   Sone, Takashi ^a   Kimura, Hideharu ^a   Nobata, Kouichi ^e   Hirose, Tatsuki ^f   Yoshimi, Yuzo ^a   Katayama, Nobuyuki ^a   Ishiura, Yoshihisa ^g   Kita, Toshiyuki ^h   Nishi, Koichi ⁱ   Nakatsumi, Yasuto ^j   Ryoma, Yoshiki ^k   Fujimura, Masaki ^a   Nakao, Shinji ^a  

^a KANAZAWA UNIVERSITY HOSPITAL   (Japan)

^b Kouseiren Takaoka Hospital   (Japan)

^c Komatsu Municipal Hospital   (Japan)

^d TOYAMA RED CROSS HOSPITAL   (Japan)

^e Kurobe City Hospital   (Japan)

^f Noto Public Hospital   (Japan)

^g Toyama City Hospital   (Japan)

^h NATIONAL HOSPITAL ORGANIZATION KANAZAWA MEDICAL CENTER   (Japan)

ⁱ ISHIKAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

^j Kanazawa Municipal Hospital   (Japan)

^k CHUGAI PHARMACEUTICAL CO LTD   (Japan)

more..

Author keywords

Malignant pleural effusion; Non small cell lung cancer; OK 432

Indexed keywords

PICIBANIL; STEROID;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG FATALITY; FEMALE; FEVER; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MALE; MULTICENTER STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THORAX PAIN; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DOSE-RESPONSE RELATIONSHIP, DRUG; DRAINAGE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PICIBANIL; PLEURAL EFFUSION, MALIGNANT;

EID: 33645815530     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Ihde DC and Minna JD: Non-small cell lung cancer. Part II: treatment. Curr Probl Cancer 15: 105-154, 1991.
2. Ryoma Y, Moriya Y, Okamoto M, Kanaya I, Saito M and Sato M: Biological effect of OK-432 (Picibanil) and possible application to dendritic cell therapy. Anticancer Res 24: 3295-3302, 2004.
3. Sakamoto J, Teramukai S, Watanabe Y, Hayata Y, Okayasu T, Nakazato H and Ohashi Y: Meta-analysis of adjuvant immunochemotherapy using OK-432 in patients with resected non-small-cell lung cancer. J Immunother 24: 250-256, 2001.
4. Yoshida K, Sugiura T, Takafuji S, Kawahara M, Matusi K, Kudoh S, Fukuoka M, Takada M, Ariyoshi Y, Ishizuka N and Saiijo N: Randomized phase II trial of three intrapleural therapy regimen in non-small cell lung cancer (NSCLC) with malignant pleural effusion (MPE): Japan Clinical Oncology Group Study (JCOG9515). Proc Am Soc Clin Oncol 20: 339a, 2001.
5. Nio Y, Nagami H, Tamura K, Tsubono M, Nio M, Sato M, Kawabata K, Hayashi H, Shiraishi T, Tsuchitani T, Mizuta J, Nakagawa M and Fukumoto M: Multi-institutional randomized clinical study on the comparative effects of intracavital chemotherapy alone versus immunotherapy alone versus immunochemotherapy for malignant effusion. Br J Cancer 80: 775-785, 1999.
6. Luh KT, Yang PC, Kuo SH, Chang DB, Yu CJ and Lee LN: Comparison of OK-432 and mitomycin C pleurodesis for malignant pleural effusion caused by lung cancer. A randomized trial. Cancer 69: 674-679, 1992.
7. Fujimoto T, Duda RB, Szilvasi A, Chen X, Mai M and O'Donnell MA: Streptococcal preparation OK-432 is a potent inducer of IL-12 and a T helper cell 1 dominant state. J Immunol 158: 5619-5626, 1997.
8. Kirkwood JM, Wilson J, Whiteside TL, Donnelly S and Herberman RB: Phase IB trial of picibanil (OK-432) as an immunomodulator in patients with resected high-risk melanoma. Cancer Immunol Immunother 44: 137-149, 1997.
9. Simon R, Wittes RE and Ellenberg SS: Randomized phase II clinical trials. Cancer Treat Rep 69: 1375-1381, 1985.
10. Ong KC, Indumathi V, Raghuram J and Ong YY: A comparative study of pleurodesis using talc slurry and bleomycin in the management of malignant pleural effusions. Respirology 5: 99-103, 2000.
11. Sahin U, Unlu M, Akkaya A and Omek Z: The value of small-bore catheter thoracostomy in the treatment of malignant pleural effusions. Respiration 68: 501-505, 2001.
12. Schulze M, Boehle AS, Kurdow R, Dohrmann P and Henne-Bruns D: Effective treatment of malignant pleural effusion by minimal invasive thoracic surgery: thoracoscopic talc pleurodesis and pleuroperitoneal shunts in 101 patients. Ann Thorac Surg 71: 1809-1812, 2001.
13. Kuzdzal J, Sladek K, Wasowski D, Soja J, Szlubowski A, Reifland A, Zieinski M and Szczeklik A: Talc powder vs. doxycycline in the control of malignant pleural effusion: a prospective, randomized trial. Med Sci Monit 9: 154-159, 2003.
14. Reeder LB: Malignant pleural effusions. Curr Treat Options Oncol 2: 93-96, 2001.
15. de Campos JR, Vargas FS, de Campos Werebe E, Cardoso P, Teixeira LR, Jatene FB and Light RW: Thoracoscopy talc poudrage: a 15-year experience. Chest 19: 801-806, 2001.
16. Sahn SA: Management of malignant pleural effusions. Monaldi Arch Chest Dis 56: 394-399, 2001.